Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Era in Cancer Diagnostics

Published: Tuesday, June 04, 2013
Last Updated: Tuesday, June 04, 2013
Bookmark and Share
Novel development for improved cancer diagnosis and treatment monitoring.

A new generation of cancer diagnostic devices has been unveiled by Singapore-based Clearbridge BioMedics, following its work with product development firm Cambridge Consultants.

The new ClearCell FX System is designed to improve cancer diagnosis and treatment monitoring by allowing doctors to rapidly isolate circulating tumour cells (CTCs) in a patient’s bloodstream - paving the way for more personalized medicine.

The ClearCell FX System separates and isolates cells in a patient’s blood sample using novel inertia focusing spiral microfluidics in the single-use CTChip FR. This allows for continuous label-free separation - i.e. without biochemical labels - of CTCs from blood cells.

The larger and denser CTCs are separated from the other blood cells within the spiral biochip due to biomechanical differences - and are then focused into an enriched cell ‘stream’.

These cell streams are channeled and collected into an enriched sample, which can be used for pathology diagnostic tests such as mutation testing for targeted therapies.

John Pritchard, head of diagnostics at Cambridge Consultants, said: “This has been a collaborative merging of our extensive experience in diagnostic device development and Clearbridge BioMedics’ expertise in cancer research and diagnostics - and it’s led to breakthrough technology that will have a huge impact on a lot of people’s lives. Our systems engineering approach, coupled with our skills in fluidics, software and compliance, has enabled us to work quickly and efficiently with Clearbridge BioMedics - even though we are thousands of miles apart.”

Clearbridge BioMedics also worked in collaboration with the National University of Singapore and the Singapore-MIT Alliance for Research and Technology (SMART) Center.

The new system - which has been designed for both research and diagnostics applications - will be undergoing regulatory approval in the US and Europe.

Johnson Chen, co-founder and managing director of Clearbridge BioMedics, said: “Once approved, it will be one of the world’s first label-free CTC enrichment systems for diagnostic use. Clearbridge BioMedics believes this system will be an ideal companion diagnostic system that complements various cancer therapies.”

Set up in late 2009, Clearbridge BioMedics is a spin-off company from the National University of Singapore. The firm’s first-generation ClearCell System - which was launched for the cancer research market in 2011 - was one of the first non-biomarker-based systems commercially available to detect, isolate and retrieve CTCs from blood.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Price is Life for Vital HIV Test
Paving the way for better HIV treatment in the world’s least-developed countries.
Thursday, October 03, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!